Beam Therapeutics Inc Market Cap ($2.60 Billion)
Market Cap & Net Worth: Beam Therapeutics Inc (BEAM)
Beam Therapeutics Inc market cap. Beam Therapeutics Inc (NASDAQ:BEAM) has a market capitalization of $2.60 Billion ($2.60 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5173 globally and #1754 in its home market, demonstrating a 16.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Beam Therapeutics Inc's stock price $28.84 by its total outstanding shares 103287665 (103.29 Million).
Beam Therapeutics Inc Market Cap History (2020–2026)
Beam Therapeutics Inc market cap history from 2020 to 2026. Data shows growth from $8.43 Billion to $2.98 Billion (6.61% CAGR). Check Beam Therapeutics Inc (BEAM) stock price for real-time trading data and today's change.
Index Memberships
Beam Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.10% | #138 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.01% | #596 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.14% | #87 of 263 |
Weight: Beam Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Beam Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Beam Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash efficiency ratio of Beam Therapeutics Inc for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
20.49x
Beam Therapeutics Inc's market cap is 20.49 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $8.43 Billion | $24.00K | -$194.59 Million | 351350.21x | N/A |
| 2021 | $8.23 Billion | $51.84 Million | -$370.64 Million | 158.76x | N/A |
| 2022 | $4.04 Billion | $60.92 Million | -$289.09 Million | 66.31x | N/A |
| 2023 | $2.81 Billion | $377.71 Million | -$132.53 Million | 7.44x | N/A |
| 2024 | $2.56 Billion | $63.52 Million | -$376.74 Million | 40.33x | N/A |
| 2025 | $2.86 Billion | $139.74 Million | -$79.99 Million | 20.49x | N/A |
Competitor Companies of BEAM by Market Capitalization
Companies near Beam Therapeutics Inc in the global market cap rankings as of October 31, 2026. See Beam Therapeutics Inc balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Beam Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Beam Therapeutics Inc (2020–2026)
Market capitalization of Beam Therapeutics Inc from 2020 to today. Between 2020 and today, Beam Therapeutics Inc's market cap moved from $8.43 Billion to $ 2.98 Billion, with a yearly change of 6.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.98 Billion | +4.04% |
| 2025 | $2.86 Billion | +11.77% |
| 2024 | $2.56 Billion | -8.89% |
| 2023 | $2.81 Billion | -30.40% |
| 2022 | $4.04 Billion | -50.92% |
| 2021 | $8.23 Billion | -2.39% |
| 2020 | $8.43 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Beam Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.60 Billion USD |
| MoneyControl | $2.60 Billion USD |
| MarketWatch | $2.60 Billion USD |
| marketcap.company | $2.60 Billion USD |
| Reuters | $2.60 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more